RMD · NYSE · STOCK
ResMed (RMD) Stock Analysis
$230.14
52W $180.27 – $277.67
63/100
$33.37B
22.0
0.75
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is RMD Bullish or Bearish?
Bullish.
Innellis AI committee rates ResMed (RMD) Buy with a composite score of 63/100
, based on 6 analysts with 67% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +11.78 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -8.22 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Risk Analyst sees a compelling case — low leverage (debt-to-equity 0.10) -- balance sheet can absorb a shock. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 23.9% shows genuine earnings power backing the valuation — Value
- 3 consecutive earnings beats -- consistent execution — Growth
- MACD histogram positive -- bullish momentum — Technical
- Low leverage (debt-to-equity 0.10) -- balance sheet can absorb a shock — Risk
- News sentiment is positive (+0.30 across 10 articles, 14d) — News
Bear Case
- Price-to-book of 4.3x prices in significant intangible value — Value
- RSI at 70 is in overbought territory — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
63/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 12%
of 192 Healthcare peers
Value Analyst
neutral
59
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 23.9% shows genuine earnings power backing the valuation
− Price-to-book of 4.3x prices in significant intangible value
Growth Analyst
bullish
60
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ 3 consecutive earnings beats -- consistent execution
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− RSI at 70 is in overbought territory
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.10) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
67
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.30 across 10 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 64.9 to 63.2.
- New bearish signals: 1 appeared.
Analyst-level changes:
- Technical Analyst: score 58->48 (-10); +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
70.3
Overbought
MACD Histogram
0.620
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Hh Hl
Support
$216.08
Resistance
$241.70
Bollinger %B
0.98
Inside Bands
Price vs Moving Averages
EMA 9
$224.77
Above
EMA 21
$224.20
Above
EMA 50
$221.99
Above
EMA 200
$225.66
Above
Fundamental Analysis
Valuation
50
Growth
74
Profitability
100
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
22.0×
P/B Ratio
5.06×
PEG Ratio
2.36
Dividend Yield
1.07%
52W High
$277.67
52W Low
$180.27
Quality & Growth
ROE
2313.1%
ROA
1699.0%
Gross Margin
6116.1%
Operating Margin
3347.8%
Revenue Growth YoY
—
Debt / Equity
0.13
AI Fundamental Assessment
P/E ratio of 22.0 (inexpensive relative to a 15-40x range); Price-to-book of 5.1x; PEG ratio of 2.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 23.1%; Return on assets of 17.0%; Net margin of 26.9%; Gross margin of 61.2%; Current ratio of 3.10 (healthy short-term liquidity); Debt-to-equity of 0.13; Free cash flow per share is positive (19.97); Most recent quarter beat estimates by 1.1%; 3 consecutive earnings beats; EPS growth roughly steady (+1.8% -> +3.1% QoQ); Analyst estimates rising over recent quarters
Get the Full RMD Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →